Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacques Cadranel

Showing results (1-10 of 329) with videos related to

Pageof 33
Sort By:
Future Oncology (London, England)|April 11, 2022
Plain language summary of publication: new information for the potential role of afatinib in treating people with <i>NRG1</i> gene fusion-positive cancerJacques Cadranel
Annals of Translational Medicine|April 4, 2018
Osimertinib in first-line treatment-is a comparison not proof?Jacques Cadranel
Revue De Pneumologie Clinique|January 24, 2007
[Target population and predictive factors of survival and efficacy of anti-HER1/EGFR drugs]Jacques Cadranel
Journal of Thoracic Disease|April 26, 2019
It's far better to be alone than to be in bad companyMichael Duruisseaux, Jacques Cadranel
Gastroenterologie Clinique Et Biologique|May 20, 2004
[Treatment considerations for hepatopulmonary syndrome]Jacques Cadranel, Camille Taillé
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 27, 2018
Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung CancerAdrien Costantini, Jacques Cadranel
La Revue Du Praticien|January 16, 2004
[Intra-thoracic opacities and masses]Marie Wislez, Jacques Cadranel
Thorax|May 31, 2007
Lung cancer in HIV infected patientsJacques Cadranel, Charles Mayaud
The European Respiratory Journal|November 2, 2015
Targeted therapy for lung cancerAnne-Pascale Meert, Jacques Cadranel
Lung|May 2, 2009
The importance of distinguishing mucinous and nonmucinous bronchioloalveolar carcinomasDavid H Garfield, Jacques Cadranel
Pageof 33

Showing results (1-10 of 329) with videos related to

Sort By:
Pageof 33
Future Oncology (London, England)|April 11, 2022
Plain language summary of publication: new information for the potential role of afatinib in treating people with <i>NRG1</i> gene fusion-positive cancerJacques Cadranel
Annals of Translational Medicine|April 4, 2018
Osimertinib in first-line treatment-is a comparison not proof?Jacques Cadranel
Revue De Pneumologie Clinique|January 24, 2007
[Target population and predictive factors of survival and efficacy of anti-HER1/EGFR drugs]Jacques Cadranel
Journal of Thoracic Disease|April 26, 2019
It's far better to be alone than to be in bad companyMichael Duruisseaux, Jacques Cadranel
Gastroenterologie Clinique Et Biologique|May 20, 2004
[Treatment considerations for hepatopulmonary syndrome]Jacques Cadranel, Camille Taillé
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 27, 2018
Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung CancerAdrien Costantini, Jacques Cadranel
La Revue Du Praticien|January 16, 2004
[Intra-thoracic opacities and masses]Marie Wislez, Jacques Cadranel
Thorax|May 31, 2007
Lung cancer in HIV infected patientsJacques Cadranel, Charles Mayaud
The European Respiratory Journal|November 2, 2015
Targeted therapy for lung cancerAnne-Pascale Meert, Jacques Cadranel
Lung|May 2, 2009
The importance of distinguishing mucinous and nonmucinous bronchioloalveolar carcinomasDavid H Garfield, Jacques Cadranel
Pageof 33